A Phase 2, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)

Study Description

The overall objective is to evaluate the efficacy, tolerability, and safety of a single dose of RBT-9 versus placebo in coronavirus disease 2019 (COVID-19) infection in non-critically ill adults who are at high risk of progression.

Study Details

Registry ID:

NCT04364763

Conditions:

COVID-19

Phase:

Phase 2

Target Enrollment:

42 participants

Start Date:

August 5, 2020

Age Range:

18–999 years

Healthy Volunteers:

No

Study Locations (5 sites)

• New Smyrna Beach, FL
  New Smyrna Beach, FloridaUnited States, United States
• Berkley, MI
  Berkley, MichiganUnited States, United States
• Houston
  Houston, TexasUnited States, United States
• Fort Worth, TX
  Fort Worth, TexasUnited States, United States
• El Paso, TX
  El Paso, TexasUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →